To Get Full Access :

Login with Linked
Login with Gmail

Follow us on

Link Linkedin Youtube

Inluriyo

Inluriyo is an oral selective estrogen receptor degrader (SERD) indicated for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. It degrades estrogen receptors to block tumor growth, offering a convenient daily oral option.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Imlunestrant

  • Innovator :

    ELI LILLY AND COMPANY

  • Approval Date :

    25-Sep-25

  • NCE-1 Date :

    25-Sep-29

  • NCE Date :

    25-Sep-30

  • Dosage Form :

    Oral Tablet

  • Strength :

    200MG

  • Therapeutic Category :

    Anticancer

  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    9

  • 2026 :

    143

  • 2027 :

    236

  • 2028 :

    341

  • 2029 :

    445

  • 2030 :

    539

  • 2031 :

    630
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Partner With Us

  • Supported 1000+ clinical trials globally
  • Provides services across regulatory, legal & clinical research
  • Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
  • Integrated CRO services as part of our offerings
  • Insights on global pricing for smarter clinical trial supply decisions
  • Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets
Contact Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login With

For full access Sign-up / Sign-in using below Methods:

Linked
Gmail

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?